ClinicalTrials.gg
RecruitingNCT05966519IntraOPUpdated Apr 8, 2026

ROSA Knee Intraoperative Planning Flexibility Study

An observational study in Osteo Arthritis Knee and Rheumatoid Arthritis, sponsored by Zimmer Biomet. Recruiting at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Zimmer Biomet · Observational

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
80
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 70 studies in Arthritis, Rheumatoid by Zimmer Biomet — 4 open to participants now, 23 under way, none of them phase 3. Arthritis, Rheumatoid · Zimmer Biomet.

Planned enrollment
31st of 43
80 · median 150
Started
2024
the only one that year
Observational
43 of 70
2 open now
Primary completion
2027-01
later than 10 of 22 live
Registered
70th of 70
by date

Among the 70 studies in Arthritis, Rheumatoid by Zimmer Biomet, this one is the 31st largest by planned enrollment of the 43 observational ones that give a count, is the only one that started in 2024, is one of 43 observational ones, reaches primary completion later than 10 of the 22 other live ones, and was the 70th registered.

Arthritis, Rheumatoid

3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 70 studies in Arthritis, Rheumatoid by Zimmer Biomet are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Arthritis, Rheumatoid by Zimmer Biomet, or all of them as a file.
02

Study summary

The purpose of this study is to verify that an orthopedic surgical assist robot (ROSA Knee System) can provide intraoperative adjustment of osteotomy angle and volume for total knee arthroplasty (TKA) based on feedbacks obtained from intraoperative soft tissue conditions. A total 80 cases will be enrolled at one study site with a postoperative follow-up period of 2 years.

Read the detailed description

The objectives of the study are to document that ROSA Knee System can provide intraoperative planning adjustment based on feedbacks obtained by laxity as well as gaps to locally preferred surgeon's operative philosophy. This will also provide accuracy, intraoperative soft tissue release as well as patient outcome on locally preferred surgical technique.

The primary endpoint is defined as the mean absolute difference between X-Atlas image-based pre-op plan \& intra-op final plan.

The secondary endpoints include Kinematic Analysis, EuroQol 5 dimensions (EQ-5D), Rehabilitation record, Knee Society Score (KSS) 2011, image assessment and Safety up to 2 years postoperatively.

03

Conditions studied

  • Osteo Arthritis Knee
  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will comprise of males and females who require primary total knee arthroplasty and satisfy the inclusion/exclusion criteria outlined in this section of the protocol. In order to avoid potential selection bias, each Investigator will offer study participation to each consecutive eligible patient presenting as a candidate for primary total knee arthroplasty using the commercially available Zimmer Biomet total knee systems. Eligible candidates who express interest in study participation will be offered Informed Consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 20 years and over
  • Skeletally matured
  • Decision to have Total Knee Arthroplasty with ROSA Knee System being made independently and prior to recruitment into study
  • Willing and able to complete scheduled follow-up evaluations as described in the study protocol
  • Has participated in the process and is willing and able to sign an Institutional Review Board (IRB)/Ethics Committee (EC) approved informed consent form

Exclusion criteria

Exclusion Criteria:

  • Has serious bone defect(s), which require(s) metallic augment, synthetic bone or allograft
  • Is septic, has an active infection or has osteomyelitis at the affected joint
  • Has vascular insufficiency, muscular atrophy at the implant site or neuromuscular disease which might jeopardize the outcome of the surgery
  • Has any concomitant disease which is likely to jeopardize the functioning or success of the implant
  • Is known to be pregnant
  • Is a prisoner, known alcohol or drug abuser or mentally incompetent or unable to understand what participation in this study entails
  • Has a known sensitivity or allergy to one or more of the implanted materials
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • TKA with ROSA Knee

    Total Knee Arthroplasty (TKA) is conducted using with robotic surgical assistant (ROSA) system

    Device: Total Knee Replacement (TKR)

Interventions

  • DeviceTotal Knee Replacement (TKR)

    Damaged cartilage of knee due to degenerative disease is replaced with metallic and plastic protheses

06

What researchers measure

Primary outcomes

  1. The mean absolute difference between X-Atlas image based pre-op plan & intra-op final plan

    The mean absolute difference between X-Atlas image-based pre-op plan and intra-op final plan in order to demonstrate the ability of the system to allow for intra-operative adjustments

    Time frame: Immediate post-operative

Secondary outcomes

  1. Pain, range of knee motion and functional performance

    The Knee Society Score 2011, and Physical Exam to evaluate pain, range of knee motion and functional performance

    Time frame: Preoperative, Postoperative 1.5 months (option), 3 months, 6 months, 12 months and 24 months

  2. QOL

    Subject quality-of-life will be measured by the EuroQol 5 dimensions 5-level (EQ-5D-5L)

    Time frame: Preoperative, Postoperative 1.5 months (option), 3 months, 6 months, 12 months and 24 months

  3. Rehabilitation record

    Recovery of patient will be assessed by prescribed Rehabilitation record and compliance

    Time frame: Preoperative, Postoperative 1.5 months (option), 3 months, 6 months, 12 months and 24 months

  4. Kinematic analysis

    Kinematic analysis will be conducted to visualize postoperative knee motion

    Time frame: Postoperative 12 months or 24 months

  5. Image review (CT/Radiograph)

    Image review (CT/Radiograph) to assess the accuracy of the implant position, radiolucency, osteolysis, atrophy, hypertrophy, component migration, device fracture, heterotopic ossification, etc.

    Time frame: Preoperative, Discharge, Postoperative 1.5 months (option), 3 months, 6 months, 12 months and 24 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jan 2027, 36 months after the start.

Of 155 industry-sponsored observational studies under Arthritis, Rheumatoid, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 113. This study's planned 36 months is below that.

Counting every sponsor, half of 391 studies reached it within 50 months; a quarter within 25 and three quarters within 113.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2023
First posted
Jul 28, 2023
StartActual
Jan 5, 2024
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2029
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05966519
Lead sponsor
Zimmer Biomet
Responsible party
Sponsor
First posted
Jul 28, 2023
Start date
Jan 5, 2024
Primary completion
Jan 2027 (estimated)
Completion
Jan 2029 (estimated)
Last update
Apr 8, 2026

Study contacts

Noriko Sugawara
Contact
noriko.sugawara@zimmerbiomet.com
+81-3-6402-6600
Yasuharu Nakashima
principal investigator · Kyushu University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion